Parkinson's Disease News and Research

Latest Parkinson's Disease News and Research

St. Jude Medical's Brio DBS system for treating Parkinson’s disease receives Australian TGA approval

St. Jude Medical, Inc., a global medical device company, today announced regulatory and reimbursement approval from the Australian Therapeutic Goods Administration of its Brio™ deep brain stimulation system for treating the symptoms of Parkinson’s disease.

23 Mar 2010

Nodality raises $15.5M to support launch of acute myelogenous leukemia test

Nodality, Inc., a biotechnology company focused on the development of next generation personalized medicine tests in cancer and autoimmune disease, today announced it completed financing in which the company raised $15.5 million.

23 Mar 2010

Rexahn Pharmaceuticals forms Parkinson’s Disease SAB to develop strategy for Serdaxin

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced the formation of its Parkinson’s Disease Scientific Advisory Board (SAB), featuring some of the leading medical researchers in neurology.

22 Mar 2010

Americans to join in Purple Day campaign to support epilepsy awareness

Members of the U.S. House and Senate, children in schools across the country, and employees of workplaces nationwide will wear purple to support epilepsy awareness on March 26. Thousands of Americans will also join the campaign by hosting Purple Day activities in their regions.

22 Mar 2010

Lab on a Chip for research on oxygen impact on brain cells

A mini-laboratory that makes it possible, among other things, to study how brain cells in stroke patients are affected by lack of oxygen is being developed by a research team at Luleå University of Technology in Sweden. Lab on a Chip is what the scientists are calling their mini-lab, which is expected to facilitate studies of all sorts of biological cells and how they are affected by different medicines, chemical substances, etc.

22 Mar 2010

Turning microRNAs into novel drugs

Researchers around the globe are working on turning microRNAs, over 5,000 of which already have been identified, into novel drugs for a wide range of applications, reports Genetic Engineering & Biotechnology News (GEN). These noncoding single-stranded RNAs act through binding to complementary mRNA sequences, thus preventing their translation into protein or accelerating mRNA breakdown, according to the March 15 issue of GEN.

20 Mar 2010

Pressure BioSciences announces presentations on advantages of PCT

Pressure BioSciences, Inc. today announced that five presentations on the advantages of pressure cycling technology (PCT) in the preparation, processing, identification, and quantification of proteins were made at last week's annual meeting of US HUPO (Human Proteomics Organization) in Denver, Colorado.

From Thermo Fisher Scientific Inc. 19 Mar 2010

Researchers use optogenetics technology to troubleshoot neural circuits

Recently, brain researchers have gained a powerful new way to troubleshoot neural circuits associated with depression, Parkinson's disease and other conditions in small animals such as rats. They use an optogenetics technology, invented at Stanford University, that precisely turns select brain cells on or off with flashes of light. Although useful, the optogenetics tool set has been limited.

19 Mar 2010

Evaluating all Medicare plan options can reduce healthcare costs

Nearly 8 million former workers have disabilities so severe that they rely on Social Security Disability Insurance benefits, and an estimated 3.3 million more will apply for disability benefits this year. For these people and others suffering from serious conditions and disabilities, taking the right steps quickly to manage costs is essential for their financial and health well-being, according to Allsup, a nationwide provider of Social Security disability representation and Medicare plan selection services.

18 Mar 2010

Findings from Study 305 evaluating the effect of Northera reported

Chelsea Therapeutics International, Ltd. reported findings from Study 305, a study evaluating the effect of Northera™ (Droxidopa), an investigational agent being studied for the treatment of neurogenic orthostatic hypotension (NOH), on patients' 24-hour blood pressure (BP) profile.

18 Mar 2010

StockPreacher.com: ACAD reports net loss of $8.7M for fourth-quarter of 2009

StockPreacher.com announces an investment report featuring ACADIA Pharmaceuticals Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

17 Mar 2010

Antidepressants effective against depression in patients suffering from physical illnesses

Antidepressants are effective against depression in patients suffering from physical illnesses, according to a new systematic review by Cochrane researchers at King's Health Partners Academic Health Sciences Centre in the UK. The researchers found the drugs were more effective than placebos at treating depression in these patients.

17 Mar 2010

Human amniotic fluid skin cells "reprogrammed" to pluripotency

In a breakthrough that may help fill a critical need in stem cell research and patient care, researchers at Mount Sinai School of Medicine have demonstrated that skin cells found in human amniotic fluid can be efficiently "reprogrammed" to pluripotency, where they have characteristics similar to human embryonic stem cells that can develop into almost any type of cell in the human body. The study is online now and will appear in print in the next issue of the journal Cellular Reprogramming, to be published next month.

16 Mar 2010

MRSA Survivors Network urges CDC to declare MRSA an epidemic

MRSA Survivors Network, the nonprofit organization, along with other advocates, urgently plead with the CDC – (Centers for Disease Control and Prevention), along with the Department of Health and Human Services (DHHS) to finally acknowledge the public health crisis to the public and take action.

16 Mar 2010

MIT biochemist joins Thomson Reuters’ annual ‘Top 12’ list

The world's "hottest" researcher is biochemist Rudolf Jaenisch from the Massachusetts Institute of Technology. He is joined by scientists scattered from Ann Arbor to Osaka on the annual Thomson Reuters list of the world's 12 hottest researchers.

16 Mar 2010

A guide on ethics and neuroscience

As scientists continue to explore how the brain works, using ever more sophisticated technology, it seems likely that new findings will radically alter the traditional understanding of human nature.

16 Mar 2010

UCL scientists explore decision-making process of human brain

The more difficult the decision we face, the more likely we are not to act, according to new research by UCL scientists that examines the neural pathways involved in 'status quo bias' in the human brain.

16 Mar 2010

Neurologix receives US PTO Notice of Allowance concerning treatment approach for epilepsy

Neurologix, Inc. today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for intellectual property central to the company’s approach to the treatment of epilepsy. The patent allowance specifically refers to Neurologix’s patent application, “Methods and Compositions for the Treatment of Neurological Disease,” which covers the treatment of seizures associated with temporal lobe epilepsy by direct administration into the brain’s temporal lobe of an AAV vector encoding Neuropeptide Y (NPY).

15 Mar 2010

New study finds green tea extract may prevent Alzheimer's disease and dementia

Long known to be beneficial in heart disease, diabetes and some cancers, a new study finds a specific green tea extract may delay or prevent Alzheimer's disease and dementia. A. Holliday & Company's "Teawell 50," is a 50 percent pure extraction of EGCG (epigallocatechin gallate) – a flavonoid which is the most potent of four major catechins in green tea.

15 Mar 2010

AED Vimpat demonstrates fewer partial-onset seizures in adults with epilepsy

UCB today announced that the antiepileptic drug (AED) Vimpat- (lacosamide) (C-V) demonstrated significantly fewer partial-onset seizures versus placebo in adults living with epilepsy, according to a Phase III clinical study published online in Epilepsia.

12 Mar 2010